Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

New Insights for Immune-Based Diagnosis and Therapy for Infectious Diseases.

Sautto GA, Diotti RA, Wisskirchen K, Kahle KM.

J Immunol Res. 2017;2017:3104719. doi: 10.1155/2017/3104719. Epub 2017 Jul 5. No abstract available.

2.

Protective Capacity of the Human Anamnestic Antibody Response during Acute Dengue Virus Infection.

Xu M, Züst R, Toh YX, Pfaff JM, Kahle KM, Davidson E, Doranz BJ, Velumani S, Tukijan F, Wang CI, Fink K.

J Virol. 2016 Nov 28;90(24):11122-11131. Print 2016 Dec 15.

3.

Functional Transplant of a Dengue Virus Serotype 3 (DENV3)-Specific Human Monoclonal Antibody Epitope into DENV1.

Messer WB, Yount BL, Royal SR, de Alwis R, Widman DG, Smith SA, Crowe JE Jr, Pfaff JM, Kahle KM, Doranz BJ, Ibarra KD, Harris E, de Silva AM, Baric RS.

J Virol. 2016 Apr 29;90(10):5090-5097. doi: 10.1128/JVI.00155-16. Print 2016 May 15.

4.

Lower IgG somatic hypermutation rates during acute dengue virus infection is compatible with a germinal center-independent B cell response.

Godoy-Lozano EE, Téllez-Sosa J, Sánchez-González G, Sámano-Sánchez H, Aguilar-Salgado A, Salinas-Rodríguez A, Cortina-Ceballos B, Vivanco-Cid H, Hernández-Flores K, Pfaff JM, Kahle KM, Doranz BJ, Gómez-Barreto RE, Valdovinos-Torres H, López-Martínez I, Rodriguez MH, Martínez-Barnetche J.

Genome Med. 2016 Feb 25;8(1):23. doi: 10.1186/s13073-016-0276-1.

5.

Broadly Neutralizing Alphavirus Antibodies Bind an Epitope on E2 and Inhibit Entry and Egress.

Fox JM, Long F, Edeling MA, Lin H, van Duijl-Richter MKS, Fong RH, Kahle KM, Smit JM, Jin J, Simmons G, Doranz BJ, Crowe JE Jr, Fremont DH, Rossmann MG, Diamond MS.

Cell. 2015 Nov 19;163(5):1095-1107. doi: 10.1016/j.cell.2015.10.050. Epub 2015 Nov 6.

6.

Dengue Virus prM-Specific Human Monoclonal Antibodies with Virus Replication-Enhancing Properties Recognize a Single Immunodominant Antigenic Site.

Smith SA, Nivarthi UK, de Alwis R, Kose N, Sapparapu G, Bombardi R, Kahle KM, Pfaff JM, Lieberman S, Doranz BJ, de Silva AM, Crowe JE Jr.

J Virol. 2015 Oct 28;90(2):780-9. doi: 10.1128/JVI.01805-15. Print 2016 Jan 15.

7.

Isolation and Characterization of Broad and Ultrapotent Human Monoclonal Antibodies with Therapeutic Activity against Chikungunya Virus.

Smith SA, Silva LA, Fox JM, Flyak AI, Kose N, Sapparapu G, Khomandiak S, Ashbrook AW, Kahle KM, Fong RH, Swayne S, Doranz BJ, McGee CE, Heise MT, Pal P, Brien JD, Austin SK, Diamond MS, Dermody TS, Crowe JE Jr.

Cell Host Microbe. 2015 Jul 8;18(1):86-95. doi: 10.1016/j.chom.2015.06.009. Erratum in: Cell Host Microbe. 2015 Sep 9;18(3):382. Khomadiak, Solomiia [corrected to Khomandiak, Solomiia].

8.

Exposure of epitope residues on the outer face of the chikungunya virus envelope trimer determines antibody neutralizing efficacy.

Fong RH, Banik SS, Mattia K, Barnes T, Tucker D, Liss N, Lu K, Selvarajah S, Srinivasan S, Mabila M, Miller A, Muench MO, Michault A, Rucker JB, Paes C, Simmons G, Kahle KM, Doranz BJ.

J Virol. 2014 Dec;88(24):14364-79. doi: 10.1128/JVI.01943-14. Epub 2014 Oct 1.

9.

HCV E2 core structures and mAbs: something is still missing.

Castelli M, Clementi N, Sautto GA, Pfaff J, Kahle KM, Barnes T, Doranz BJ, Dal Peraro M, Clementi M, Burioni R, Mancini N.

Drug Discov Today. 2014 Dec;19(12):1964-70. doi: 10.1016/j.drudis.2014.08.011. Epub 2014 Aug 27. Review.

10.

Dengue virus envelope protein domain I/II hinge determines long-lived serotype-specific dengue immunity.

Messer WB, de Alwis R, Yount BL, Royal SR, Huynh JP, Smith SA, Crowe JE Jr, Doranz BJ, Kahle KM, Pfaff JM, White LJ, Sariol CA, de Silva AM, Baric RS.

Proc Natl Acad Sci U S A. 2014 Feb 4;111(5):1939-44. doi: 10.1073/pnas.1317350111. Epub 2014 Jan 2. Erratum in: Proc Natl Acad Sci U S A. 2014 Apr 22;111(16):6115. Retraction in: Proc Natl Acad Sci U S A. 2015 May 19;112(20):E2738.

11.

The potent and broadly neutralizing human dengue virus-specific monoclonal antibody 1C19 reveals a unique cross-reactive epitope on the bc loop of domain II of the envelope protein.

Smith SA, de Alwis AR, Kose N, Harris E, Ibarra KD, Kahle KM, Pfaff JM, Xiang X, Doranz BJ, de Silva AM, Austin SK, Sukupolvi-Petty S, Diamond MS, Crowe JE Jr.

MBio. 2013 Nov 19;4(6):e00873-13. doi: 10.1128/mBio.00873-13.

12.

Atomic-level functional model of dengue virus Envelope protein infectivity.

Christian EA, Kahle KM, Mattia K, Puffer BA, Pfaff JM, Miller A, Paes C, Davidson E, Doranz BJ.

Proc Natl Acad Sci U S A. 2013 Nov 12;110(46):18662-7. doi: 10.1073/pnas.1310962110. Epub 2013 Oct 24.

13.

A neutralizing monoclonal antibody targeting the acid-sensitive region in chikungunya virus E2 protects from disease.

Selvarajah S, Sexton NR, Kahle KM, Fong RH, Mattia KA, Gardner J, Lu K, Liss NM, Salvador B, Tucker DF, Barnes T, Mabila M, Zhou X, Rossini G, Rucker JB, Sanders DA, Suhrbier A, Sambri V, Michault A, Muench MO, Doranz BJ, Simmons G.

PLoS Negl Trop Dis. 2013 Sep 12;7(9):e2423. doi: 10.1371/journal.pntd.0002423. eCollection 2013.

14.

Mechanistic study of broadly neutralizing human monoclonal antibodies against dengue virus that target the fusion loop.

Costin JM, Zaitseva E, Kahle KM, Nicholson CO, Rowe DK, Graham AS, Bazzone LE, Hogancamp G, Figueroa Sierra M, Fong RH, Yang ST, Lin L, Robinson JE, Doranz BJ, Chernomordik LV, Michael SF, Schieffelin JS, Isern S.

J Virol. 2013 Jan;87(1):52-66. doi: 10.1128/JVI.02273-12. Epub 2012 Oct 17.

15.

Asymmetric deactivation of HIV-1 gp41 following fusion inhibitor binding.

Kahle KM, Steger HK, Root MJ.

PLoS Pathog. 2009 Nov;5(11):e1000674. doi: 10.1371/journal.ppat.1000674. Epub 2009 Nov 26.

Supplemental Content

Loading ...
Support Center